PL1696931T3 - Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych - Google Patents
Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznychInfo
- Publication number
- PL1696931T3 PL1696931T3 PL04815318T PL04815318T PL1696931T3 PL 1696931 T3 PL1696931 T3 PL 1696931T3 PL 04815318 T PL04815318 T PL 04815318T PL 04815318 T PL04815318 T PL 04815318T PL 1696931 T3 PL1696931 T3 PL 1696931T3
- Authority
- PL
- Poland
- Prior art keywords
- analogs
- methods
- cycloheptene
- treatment
- amino substituted
- Prior art date
Links
- 125000001162 cycloheptenyl group Chemical class C1(=CCCCCC1)* 0.000 title 1
- 239000000472 muscarinic agonist Substances 0.000 title 1
- 150000001408 amides Chemical class 0.000 abstract 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004170 clozapine Drugs 0.000 abstract 1
- 150000001933 cycloheptenes Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53192703P | 2003-12-22 | 2003-12-22 | |
| US54809004P | 2004-02-24 | 2004-02-24 | |
| US54860404P | 2004-02-27 | 2004-02-27 | |
| EP04815318A EP1696931B1 (en) | 2003-12-22 | 2004-12-21 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| PCT/US2004/043224 WO2005063254A2 (en) | 2003-12-22 | 2004-12-21 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1696931T3 true PL1696931T3 (pl) | 2009-10-30 |
Family
ID=34743692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04815318T PL1696931T3 (pl) | 2003-12-22 | 2004-12-21 | Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US7550454B2 (https=) |
| EP (2) | EP2088147A1 (https=) |
| JP (1) | JP2007534656A (https=) |
| KR (1) | KR101157881B1 (https=) |
| CN (1) | CN101962369A (https=) |
| AT (1) | ATE426405T1 (https=) |
| AU (1) | AU2004308955B2 (https=) |
| BR (1) | BRPI0417749A (https=) |
| CA (1) | CA2550735A1 (https=) |
| CY (1) | CY1109171T1 (https=) |
| DE (1) | DE602004020263D1 (https=) |
| DK (1) | DK1696931T3 (https=) |
| ES (1) | ES2324713T3 (https=) |
| IL (1) | IL176447A0 (https=) |
| MX (1) | MXPA06007244A (https=) |
| NO (1) | NO20063371L (https=) |
| NZ (1) | NZ547911A (https=) |
| PL (1) | PL1696931T3 (https=) |
| PT (1) | PT1696931E (https=) |
| SG (1) | SG133606A1 (https=) |
| SI (1) | SI1696931T1 (https=) |
| WO (1) | WO2005063254A2 (https=) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2278729T3 (es) | 2000-03-06 | 2007-08-16 | Acadia Pharmaceuticals Inc. | Compuestos azaciclicos para usar en el tratamiento de enfermedades relacionadas con la serotonina. |
| MXPA04006280A (es) | 2001-12-28 | 2004-09-27 | Acadia Pharm Inc | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. |
| AU2003235435A1 (en) * | 2002-03-20 | 2003-10-08 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of quetiapine hemifumarate |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| EP1562937A2 (en) | 2002-06-24 | 2005-08-17 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| DK2009000T3 (da) | 2003-01-16 | 2011-09-05 | Acadia Pharm Inc | Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme |
| US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| CN1741803A (zh) * | 2003-01-23 | 2006-03-01 | 阿卡蒂亚药品公司 | N－脱甲基氯氮平在治疗人神经精神疾病中的用途 |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| SG133606A1 (en) | 2003-12-22 | 2007-07-30 | Acadia Pharm Inc | Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| US20090239840A1 (en) * | 2003-12-22 | 2009-09-24 | Acadia Pharmaceuticals, Inc. | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| JP2007536216A (ja) * | 2004-04-01 | 2007-12-13 | アカディア ファーマシューティカルズ，インコーポレーテッド | 固体ｎ−デスメチルクロザピンおよびその結晶形を合成および単離する方法 |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| TW200621244A (en) | 2004-08-19 | 2006-07-01 | Vertex Pharma | Modulators of muscarinic receptors |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| CA2580129A1 (en) * | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
| US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| JP2008521825A (ja) * | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| WO2006073360A1 (en) * | 2005-01-07 | 2006-07-13 | Astrazeneca Ab | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| WO2006107948A2 (en) * | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents |
| JP2008502707A (ja) * | 2005-04-14 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | クエチアピンフマレートの調製方法 |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US20080090805A1 (en) * | 2005-10-17 | 2008-04-17 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| EP1937614A1 (en) * | 2005-10-17 | 2008-07-02 | Arcadia Pharmaceuticals Inc. | Iron catalyzed cross-coupling reactions of imidoyl derivatives |
| CA2625423A1 (en) * | 2005-10-17 | 2007-04-26 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| WO2007053618A1 (en) * | 2005-10-31 | 2007-05-10 | Acadia Pharmaceuticals Inc. | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20070105835A1 (en) * | 2005-11-07 | 2007-05-10 | Kazantsev Aleksey G | Compositions and methods for modulating poly(ADP-ribose) polymerase activity |
| WO2007062339A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| WO2007062336A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Salt forms |
| CN101426499A (zh) | 2006-02-22 | 2009-05-06 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007133802A2 (en) * | 2006-05-15 | 2007-11-22 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
| DE102006032427A1 (de) * | 2006-07-13 | 2008-01-17 | Neuraxpharm Arzneimittel Gmbh U. Co. Kg | Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung |
| DE102006032426A1 (de) * | 2006-07-13 | 2008-01-17 | Neuraxpharm Arzneimittel Gmbh U. Co. Kg | Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung |
| WO2008021545A2 (en) * | 2006-08-18 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| EP2120957A4 (en) * | 2006-12-20 | 2011-05-04 | Astrazeneca Ab | COMPOUNDS AND USES THEREOF |
| US20100016284A1 (en) * | 2006-12-20 | 2010-01-21 | Astrazeneca Ab | Compounds and uses thereof - 151 |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| US8093237B2 (en) * | 2007-03-15 | 2012-01-10 | Aryx Therapeutics, Inc. | Dibenzo[b,f][1,4]oxazapine compounds |
| CA2681506C (en) | 2007-03-19 | 2016-05-24 | Perry Peters | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| MX2010003373A (es) * | 2007-10-03 | 2010-04-30 | Vertex Pharma | Moduladores de receptores muscarinicos. |
| WO2009149347A1 (en) | 2008-06-05 | 2009-12-10 | President And Fellows Of Harvard College | High-valent palladium fluoride complexes and uses thereof |
| MX2010014203A (es) * | 2008-06-20 | 2011-02-22 | Astrazeneca Ab | Derivados de dibenzotiazepina y sus usos - 424. |
| WO2010062565A1 (en) * | 2008-10-27 | 2010-06-03 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| AU2009316478A1 (en) | 2008-11-20 | 2010-05-27 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| EP2385944A4 (en) * | 2009-01-09 | 2013-06-19 | Harvard College | FLUORINARY COMPOUNDS AND METHOD OF USE THEREOF |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN101531570B (zh) * | 2009-04-17 | 2012-10-10 | 中国科学院上海有机化学研究所 | 1，2-取代-5-乙炔基-(或10，11-二氢)-5H-二苯基[a，d]环庚烯(烷)-5-醇、合成方法及用途 |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| PT3061821T (pt) | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| WO2011025748A1 (en) * | 2009-08-26 | 2011-03-03 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl [a, d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| WO2012142162A2 (en) | 2011-04-12 | 2012-10-18 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| US9273083B2 (en) | 2012-09-26 | 2016-03-01 | President And Fellows Of Harvard College | Nickel fluorinating complexes and uses thereof |
| CA2923835C (en) * | 2013-09-11 | 2022-11-29 | The Administrators Of The Tulane Educational Fund | Novel anthranilic amides and the use thereof |
| WO2015058047A2 (en) | 2013-10-18 | 2015-04-23 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| CN104016937B (zh) * | 2014-05-09 | 2016-12-07 | 中科院广州化学有限公司 | 一种n-芳基氧氮杂卓酮类化合物及其制备方法 |
| EP4212536B1 (en) | 2015-07-02 | 2025-02-19 | F. Hoffmann-La Roche AG | Benzoxazepin oxazolidinone compounds and methods of use |
| ES2890492T3 (es) | 2015-07-20 | 2022-01-20 | Acadia Pharm Inc | Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| WO2018139471A1 (ja) * | 2017-01-25 | 2018-08-02 | 大日本住友製薬株式会社 | ジベンゾジアゼピン誘導体 |
| WO2018148529A1 (en) | 2017-02-10 | 2018-08-16 | Florida A&M University | Identification of agents displaying functional activation of dopamine d2 and d4 receptors |
| EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| AU2018346358A1 (en) | 2017-10-06 | 2020-04-09 | Leyden Technologies B.V. | Stable solutions of multicyclic antidepressants |
| CN107903244B (zh) * | 2017-11-29 | 2019-06-14 | 武汉珈创生物技术股份有限公司 | 具有抗肿瘤活性的2-胺基取代苯并二氮卓化合物及其制备方法 |
| EP3746126B1 (en) | 2018-01-30 | 2024-07-31 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea or simple snoring |
| JP2021104931A (ja) * | 2018-02-22 | 2021-07-26 | 大日本住友製薬株式会社 | 含窒素複素環を有するジベンゾアゼピン誘導体 |
| CN118878470A (zh) * | 2018-06-25 | 2024-11-01 | 北京安博睿达医药科技有限公司 | 一种新的喹硫平类似物及其制备方法和应用 |
| KR102408292B1 (ko) | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| JP7696354B2 (ja) | 2019-10-21 | 2025-06-20 | アライリオン インコーポレイテッド | 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体 |
| CN112358455B (zh) * | 2020-11-16 | 2022-07-19 | 吉林奥来德光电材料股份有限公司 | 一种二苯并七元杂环类化合物及其制备方法与应用 |
| TWI820605B (zh) * | 2022-02-18 | 2023-11-01 | 國立臺灣大學 | 抗菌化合物、其製備方法及其用途 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR870763A (fr) | 1939-12-19 | 1942-03-24 | Zeiss Ikon Ag | Procédé destiné à faire disparaître les bruits produits par les boucles du film dans les appareils de prise de vues et de reproduction, en particulier pour la priseet la reproduction de films sonores |
| CH240228A (de) | 1944-07-28 | 1945-12-15 | Ciba Geigy | Schaumisoliermasse auf Kunstharzbasis. |
| FR939591A (fr) | 1946-01-09 | 1948-11-18 | Philips Nv | Récepteur de télévision |
| FR939595A (fr) | 1947-01-08 | 1948-11-18 | Perfectionnements apportés aux tuiles à recouvrement en matériaux de toute nature | |
| FR51M (https=) | 1960-06-03 | 1960-11-28 | ||
| CH422793A (de) * | 1961-07-20 | 1966-10-31 | Wander Ag Dr A | Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine |
| FR1334944A (fr) | 1961-08-11 | 1963-08-16 | Wander Ag Dr A | Procédé de préparation d'amidines de la série des 5-dibenzo-[b,e] [1,4]-diazépines |
| DE1620711A1 (de) * | 1962-05-25 | 1970-06-04 | Wander Ag Dr A | Verfahren zur Herstellung 11-basisch substituierter 5H-Dibenzo[b,e][1,4]diazepine |
| CH476743A (de) | 1962-06-08 | 1969-08-15 | Wander Ag Dr A | Verfahren zur Herstellung von Amidinen der Dibenzo (b,e) (1,4)-diazepin-Reihe |
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| US3389139A (en) * | 1963-06-14 | 1968-06-18 | Wander Ag Dr A | 6-homopiperazino and piperazinomorphanthridines |
| GB1006156A (en) | 1963-06-14 | 1965-09-29 | Wander Ag Dr A | 6-basic substituted morphanthridines |
| US3884920A (en) * | 1967-07-14 | 1975-05-20 | Sandoz Ag | 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines |
| US3908010A (en) * | 1967-03-22 | 1975-09-23 | Wander Ag Dr A | Basically substituted heterocycles as anti-emetics |
| AT252925B (de) | 1964-05-27 | 1967-03-10 | Wander Ag Dr A | Verfahren zur Herstellung neuer 11-basisch substituierter Dibenz[b,f][1,4]oxazepine |
| US3412193A (en) * | 1965-12-13 | 1968-11-19 | American Cyanamid Co | 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility |
| AT278805B (de) * | 1966-01-17 | 1970-02-10 | American Cyanamid Co | Verfahren zur herstellung von oxazepinen und thiazepinen |
| GB1184251A (en) * | 1966-04-15 | 1970-03-11 | American Cyanamid Co | Oxazepines and Thiazepines |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| NL6715650A (https=) | 1966-12-16 | 1968-06-17 | ||
| GB1177956A (en) | 1966-12-23 | 1970-01-14 | American Cyanamid Co | Production of Oxazepines and Thiazepines |
| CA979441A (en) | 1967-02-27 | 1975-12-09 | American Cyanamid Company | 11-(piperazinyl) dibenz (b,f) (1,4) oxazepines and analogous thiazepines |
| DE1720007A1 (de) | 1967-03-13 | 1971-05-19 | Wander Ag Dr A | Basisch substituierte Heterocyclen |
| CH514612A (de) | 1967-03-13 | 1971-10-31 | Wander Ag Dr A | Verfahren zur Herstellung 11-basisch substituierter Dibenz(b,f)-1,4-oxazepine und Dibenzo(b,e)-1,4-diazepine |
| US3852446A (en) * | 1967-03-13 | 1974-12-03 | Sandoz Ag | Organic compounds in treatment of psychotic disturbances |
| US3758479A (en) * | 1967-03-22 | 1973-09-11 | Sandoz Ag | Nitro and sulphamoyl substituted dibenzodiazepines |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3751415A (en) * | 1967-03-22 | 1973-08-07 | Sandoz Ag | 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines |
| CA918659A (en) * | 1969-07-31 | 1973-01-09 | Yoshitomi Pharmaceutical Industries | 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines |
| NL7110453A (https=) | 1970-08-06 | 1972-02-08 | Wander Ag Dr A | |
| US3660406A (en) * | 1970-10-26 | 1972-05-02 | American Cyanamid Co | 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines |
| CH555856A (de) * | 1971-05-04 | 1974-11-15 | Hoffmann La Roche | Verfahren zur herstellung von tricyclischen verbindungen. |
| US3962248A (en) * | 1972-04-04 | 1976-06-08 | Sandoz, Inc. | Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines |
| CH569730A5 (https=) | 1972-04-04 | 1975-11-28 | Wander Ag Dr A | |
| CH585222A5 (en) | 1973-02-14 | 1977-02-28 | Wander Ag Dr A | Prepn. of antipsychotic heterocyclic piperazine derivs. - by reaction of heterocyclic ketones with metal piperazine complexes |
| NL7403657A (https=) | 1973-03-23 | 1974-09-25 | ||
| US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
| DE2625258A1 (de) | 1975-06-06 | 1976-12-09 | Hoffmann La Roche | Dibenzo eckige klammer auf b,f eckige klammer zu thiepinderivat |
| FI762646A7 (https=) | 1975-09-24 | 1977-03-25 | Sandoz Ag | |
| US4045445A (en) * | 1975-12-14 | 1977-08-30 | American Cyanamid Company | 11-(4-Piperidyl)dibenzo-diazepines |
| CS179793B1 (en) | 1976-02-13 | 1977-11-30 | Miroslav Protiva | Biological derivative of 11-/4-methylpiperazino/-5h-dib)nzo/b,e/-1,4-diazepine |
| CH601288A5 (en) | 1976-06-09 | 1978-07-14 | Sandoz Ag | 11-Piperazino-5H-di:benzodiazepine derivs. |
| US4406900A (en) * | 1976-11-10 | 1983-09-27 | Sandoz Ltd. | Neuroleptic use of morphanthridines |
| CH624682A5 (https=) * | 1976-11-10 | 1981-08-14 | Sandoz Ag | |
| US4191760A (en) * | 1977-02-23 | 1980-03-04 | Abbott Laboratories | Dibenzodiazepines |
| US4097597A (en) * | 1977-02-23 | 1978-06-27 | Abbott Laboratories | Dibenzo b,e! 1,4!diazepines |
| US4096261A (en) * | 1977-02-23 | 1978-06-20 | Abbott Laboratories | Dibenzodiazepines |
| DD133235A1 (de) | 1977-10-10 | 1978-12-20 | Carla Rueger | Verfahren zur herstellung von in 11-stellung basisch substituierten 5h-dibenzo eckige klammer auf b,e eckige klammer zu eckige klammer auf 1,4 eckige klammer zu diazepinen |
| CS196893B1 (en) * | 1977-12-22 | 1980-04-30 | Miroslav Protiva | 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines |
| US4263207A (en) * | 1978-08-01 | 1981-04-21 | Merck & Co., Inc. | 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof |
| US4404137A (en) * | 1979-10-16 | 1983-09-13 | Lilly Industries Limited | Pyrazolo [3,4-b][1,5]benzodiazepine compounds |
| US4764616A (en) | 1983-05-18 | 1988-08-16 | Hoechst-Roussel Pharmaceuticals Inc. | Benzopyrrolobenzodiazepines and quinobenzodiazepines |
| US4663453A (en) * | 1983-05-18 | 1987-05-05 | Hoechst-Roussel Pharmaceuticals Inc. | Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| JPH04211071A (ja) * | 1990-03-05 | 1992-08-03 | Hokuriku Seiyaku Co Ltd | 多環式化合物 |
| BE1004596A4 (fr) | 1990-09-26 | 1992-12-22 | Therabel Res S A N V | Derives de methylpiperazinoazepine, leur preparation et leur utilisation. |
| US5817655A (en) * | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Methods of treatment using a thieno-benzodiazepine |
| US5300422A (en) * | 1991-12-04 | 1994-04-05 | Case Western Reserve University | Screening method for controlling agranulocytosis |
| US5393752A (en) * | 1992-05-26 | 1995-02-28 | Therabel Research S.A./N.V. | Methylpiperazinoazepine compounds, preparation and use thereof |
| WO1994026107A1 (en) * | 1993-05-13 | 1994-11-24 | New York University | Psychosis protecting nucleic acid, peptides, compositions and method of use |
| US5354747A (en) * | 1993-06-16 | 1994-10-11 | G. D. Searle & Co. | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| US5538965A (en) * | 1993-12-23 | 1996-07-23 | Allelix Biopharmaceuticals Inc. | Dopamine receptor ligands |
| US6566065B1 (en) * | 1994-05-26 | 2003-05-20 | Mcgill University | Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene |
| GB2292685A (en) | 1994-07-27 | 1996-03-06 | Sankyo Co | Allosteric effectors at muscarinic receptors |
| US5602120A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Benzyl-substituted compounds having dopamine receptor affinity |
| US5602121A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Alkyl-substituted compounds having dopamine receptor affinity |
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| US5700445A (en) * | 1994-12-12 | 1997-12-23 | Allelix Biopharmaceuticals, Inc. | N-methyl piperazine compounds having dopamine receptor affinity |
| SE9500998D0 (sv) * | 1995-03-19 | 1995-03-19 | Haakan Wilhelm Wikstroem | New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics |
| GB9617305D0 (en) * | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| NZ525108A (en) | 1998-03-31 | 2005-02-25 | Acadia Pharm Inc | Compounds with activity on muscarinic receptors |
| GB9924962D0 (en) | 1999-10-21 | 1999-12-22 | Mrc Collaborative Centre | Allosteric sites on muscarinic receptors |
| CN1249051C (zh) * | 2000-04-28 | 2006-04-05 | 阿卡蒂亚药品公司 | 毒蕈碱性激动剂 |
| AU2002249885A1 (en) | 2000-11-17 | 2002-08-12 | Adolor Corporation | Delta agonist analgesics |
| US6890919B2 (en) | 2001-06-26 | 2005-05-10 | Shitij Kapur | Atypical antipsychotic agents having low affinity for the D2 receptor |
| US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| DE10206941A1 (de) | 2002-02-19 | 2003-09-25 | Goetz Nowak | Neue Arzneimittel |
| AU2003217936A1 (en) | 2002-03-28 | 2003-10-13 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| CN1681388A (zh) | 2002-09-18 | 2005-10-12 | Fmc有限公司 | 三环衍生物杀虫剂 |
| AU2003290079A1 (en) | 2002-12-20 | 2004-07-14 | Basf Aktiengesellschaft | Pesticidal dibenzo(hetero)azepine derivatives |
| DK2009000T3 (da) | 2003-01-16 | 2011-09-05 | Acadia Pharm Inc | Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme |
| CN1741803A (zh) * | 2003-01-23 | 2006-03-01 | 阿卡蒂亚药品公司 | N－脱甲基氯氮平在治疗人神经精神疾病中的用途 |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20070275957A1 (en) * | 2003-01-23 | 2007-11-29 | Weiner David M | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| EP1596867A4 (en) | 2003-02-19 | 2006-03-22 | Merck & Co Inc | TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR |
| DE10310196A1 (de) | 2003-03-06 | 2004-09-23 | Rina-Netzwerk Rna Technologien Gmbh | Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose |
| ES2349091T3 (es) | 2003-07-02 | 2010-12-27 | Astrazeneca Ab | Metabolito de quetiapina. |
| SG133606A1 (en) * | 2003-12-22 | 2007-07-30 | Acadia Pharm Inc | Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| JP4847320B2 (ja) | 2004-02-20 | 2011-12-28 | 大日本住友製薬株式会社 | 統合失調症の記憶・学習機能障害治療薬のｉｎｖｉｖｏスクリーニング方法 |
| JP2007536216A (ja) * | 2004-04-01 | 2007-12-13 | アカディア ファーマシューティカルズ，インコーポレーテッド | 固体ｎ−デスメチルクロザピンおよびその結晶形を合成および単離する方法 |
| EP1778244A1 (en) | 2004-08-05 | 2007-05-02 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| US20060063754A1 (en) * | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| EP1804804B1 (en) | 2004-09-21 | 2012-01-25 | Hypnion, Inc. | 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS |
| US7563785B2 (en) | 2004-10-29 | 2009-07-21 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
| WO2006081327A2 (en) | 2005-01-25 | 2006-08-03 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
| MX2007009797A (es) | 2005-02-14 | 2007-11-06 | Combinatorx Inc | Compuestos y sus usos. |
| WO2006107948A2 (en) | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents |
| WO2007053618A1 (en) * | 2005-10-31 | 2007-05-10 | Acadia Pharmaceuticals Inc. | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| US20090215744A1 (en) | 2005-11-18 | 2009-08-27 | Astrazeneca Ab | Solid Formulations |
| WO2007062339A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| WO2007062336A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Salt forms |
| EP1951257A4 (en) | 2005-11-18 | 2008-11-05 | Astrazeneca Ab | CRYSTALLINE FORMS |
| WO2008002602A1 (en) | 2006-06-27 | 2008-01-03 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine to treat psychosis |
| WO2008066620A2 (en) | 2006-10-20 | 2008-06-05 | Concert Pharmaceuticals Inc. | Dibenzothiazepine derivatives |
-
2004
- 2004-12-21 SG SG200704645-1A patent/SG133606A1/en unknown
- 2004-12-21 CA CA002550735A patent/CA2550735A1/en not_active Abandoned
- 2004-12-21 AU AU2004308955A patent/AU2004308955B2/en not_active Ceased
- 2004-12-21 EP EP09155868A patent/EP2088147A1/en not_active Withdrawn
- 2004-12-21 DE DE602004020263T patent/DE602004020263D1/de not_active Expired - Lifetime
- 2004-12-21 EP EP04815318A patent/EP1696931B1/en not_active Expired - Lifetime
- 2004-12-21 BR BRPI0417749-5A patent/BRPI0417749A/pt not_active IP Right Cessation
- 2004-12-21 NZ NZ547911A patent/NZ547911A/en not_active IP Right Cessation
- 2004-12-21 AT AT04815318T patent/ATE426405T1/de active
- 2004-12-21 SI SI200431143T patent/SI1696931T1/sl unknown
- 2004-12-21 WO PCT/US2004/043224 patent/WO2005063254A2/en not_active Ceased
- 2004-12-21 MX MXPA06007244A patent/MXPA06007244A/es active IP Right Grant
- 2004-12-21 KR KR1020067014864A patent/KR101157881B1/ko not_active Expired - Fee Related
- 2004-12-21 DK DK04815318T patent/DK1696931T3/da active
- 2004-12-21 PT PT04815318T patent/PT1696931E/pt unknown
- 2004-12-21 JP JP2006547344A patent/JP2007534656A/ja not_active Withdrawn
- 2004-12-21 US US11/019,555 patent/US7550454B2/en not_active Expired - Fee Related
- 2004-12-21 PL PL04815318T patent/PL1696931T3/pl unknown
- 2004-12-21 CN CN2010102389158A patent/CN101962369A/zh active Pending
- 2004-12-21 ES ES04815318T patent/ES2324713T3/es not_active Expired - Lifetime
-
2006
- 2006-05-03 US US11/417,859 patent/US7517871B2/en not_active Expired - Fee Related
- 2006-05-03 US US11/417,441 patent/US7491715B2/en not_active Expired - Fee Related
- 2006-06-20 IL IL176447A patent/IL176447A0/en unknown
- 2006-07-20 NO NO20063371A patent/NO20063371L/no not_active Application Discontinuation
-
2007
- 2007-04-10 US US11/733,476 patent/US7622461B2/en not_active Expired - Fee Related
-
2009
- 2009-06-25 CY CY20091100666T patent/CY1109171T1/el unknown
- 2009-11-18 US US12/621,435 patent/US20100129473A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG133606A1 (en) | Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | |
| WO2008021463A3 (en) | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | |
| WO2002074758A3 (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
| IL165696A0 (en) | Substituted 1,3-diphenykprop-2-en-1-one derivatives and preparation and uses thereof | |
| AP2004003123A0 (en) | Thiazole and oxazole derivatives that modulate PPAR activity | |
| IL213649A0 (en) | Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament | |
| AU2003206413A8 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| PL369776A1 (en) | Process for producing l-amino acid using escherichia | |
| AU2003284968A8 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
| AP1791A (en) | Amino acids with affinity for the ?2?-protein. | |
| AU8830801A (en) | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders | |
| DK1246625T3 (da) | Anvendelser og sammensætninger af nitratestere til tilvejebringelse af sedering | |
| MY138547A (en) | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | |
| WO2004026258A3 (en) | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease | |
| WO2003057213A3 (en) | Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor | |
| AU2003303141A8 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| TW200511989A (en) | Methods for using amino acids with affinity for the α 2 δ-protein | |
| TW200728300A (en) | Therapeutic agents | |
| EP1619185A4 (en) | 4,4-DIFLUOR-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVE OR SALT THEREOF | |
| BR0308753A (pt) | Método para produzir pseudo-ilhotas | |
| PL1716147T3 (pl) | Pochodne diazaspiropiperydyny jako inhibitory transportera 1 glicyny i transportera 2 glicyny | |
| CA2387394A1 (en) | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder | |
| GB0326845D0 (en) | Stand for the toothbrush's head | |
| ZA200504565B (en) | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system |